CAMBRIDGE, Mass., May 10, 2018 – Semma Therapeutics, Inc., a biotechnology company pioneering the curative use of stem cells in regenerative medicine, today announced the appointment of Bastiano Sanna, Ph.D., as Chief Executive Officer and President. Dr. Sanna will succeed Elizabeth Stoner, M.D., who has been serving as the Interim CEO and will remain as an advisor to the Company.
Highly Oversubscribed Financing Brings Together Leading Syndicate of Investors to Advance Clinical Development of Novel Cell Therapy for Type 1 Diabetes
CAMBRIDGE, Mass., November 30, 2017 – Semma Therapeutics, a biotechnology company focused on the development of novel regenerative medicines, announced today the successful completion of a highly oversubscribed $114 million Series B financing. Proceeds will be used to bring Semma’s lead development program, encapsulated stem cell-derived islets, through clinical proof-of-concept in patients and to continue exploration of other regenerative medicine therapeutics. Semma’s proprietary technologies enable the generation of billions of functional, insulin-producing beta cells which have the potential to control blood sugar in people living with diabetes.
CAMBRIDGE, Mass., October 4, 2017 – Semma Therapeutics, a biopharmaceutical company developing stem cell-derived islet (SC-islet) technology for type 1 diabetes (T1D), today announced it will present on its encapsulated stem cell-derived human islets in a company overview at the Cell & Gene Meeting on the Mesa at 9:30 a.m. PDT on Thursday, Oct. 5 in La Jolla, California.
CAMBRIDGE, Mass., March 22, 2017 – Semma Therapeutics, a biopharmaceutical company developing Stem Cell-derived Islet therapy for type 1 diabetes (T1D), today announced it has received an investment from the JDRF T1D Fund, a venture philanthropy fund exclusively devoted to finding and funding the best early-stage T1D commercial opportunities. Financial terms of the investment were not disclosed.
CAMBRIDGE, Mass., November 7, 2016 – Semma Therapeutics, a biopharmaceutical company developing cellular therapies for the treatment of diabetes, announced today that Mark Fishman, M.D., has joined its Board of Directors as Chairman.